
|Articles|August 4, 2003
Many could benefit from BPH drug with unique technology
Men with benign prostatic hyperplasia (BPH) will soon have a therapeutic option that uses a unique drug delivery system. The FDA recently approved alfuzosin (UroXatral, Sanofi-Synthelabo) extended-release tablets for the treatment of the signs and symptoms of BPH. Alfuzosin is not indicated for the treatment of hypertension. The manufacturer expects alfuzosin to be available in pharmacies sometime in the second half of 2003.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Severe COVID-19 Increases Stroke Risk for Patients With Asthma
2
The Variety of Migraine Treatment Options Opens the Door for Pharmacy Services | NCPA 2025
3
The Rise in Supplement Use Calls for Pharmacist-Led Counseling, Education | NCPA 2025
4
How Community Pharmacists Are Proactively Managing Patients’ Migraines | NCPA 2025
5